Who Owns Apellis Pharmaceuticals Company?

Apellis Pharmaceuticals Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Apellis Pharmaceuticals?

Delving into the ownership structure of a biopharmaceutical giant like Apellis Pharmaceuticals is key to understanding its future. The shifts in ownership often mirror the company's strategic pivots and market successes. Understanding the Apellis Pharmaceuticals SWOT Analysis is crucial to assess its position. This exploration provides a comprehensive view of who controls the company's destiny.

Apellis Pharmaceuticals, founded in 2009, has seen its ownership evolve significantly, especially with its focus on complement-mediated diseases. Examining the company's ownership reveals insights into its strategic direction and potential growth. Knowing who the major stakeholders are—from early investors to current shareholders—is vital for anyone tracking the Apellis stock and its trajectory. This analysis will cover key aspects, including Apellis investors and Apellis management influence.

Apellis Pharmaceuticals, a company focused on complement-based therapies, was co-founded by Cedric Francois, M.D., Ph.D., and Alec Machiels, M.D., Ph.D. Dr. Francois served as President and CEO, bringing his medical background and vision to the company. Dr. Machiels also played a key role in the company's scientific and strategic direction. Understanding the founders and early ownership provides a crucial foundation for analyzing the company's trajectory.

The founders' vision and strategic approach were fundamental in attracting initial investment and shaping the early distribution of control. While specific initial equity splits are not publicly detailed, it's typical for founders in early-stage biopharmaceutical ventures to retain a significant portion of ownership. This often involves vesting schedules to ensure their long-term commitment.

Early backing for Apellis likely came from angel investors and venture capital firms specializing in life sciences. These early investors provided the crucial seed funding necessary for preclinical research and development, acquiring equity stakes in exchange for their capital. Such initial agreements often include provisions like vesting schedules and buy-sell clauses.

Founders' Roles

Cedric Francois, M.D., Ph.D., served as President and CEO, while Alec Machiels, M.D., Ph.D., contributed to the scientific and strategic direction. Their combined expertise was crucial in the company's early stages.

Early Investment

Early funding likely came from angel investors and venture capital firms. These early backers provided the necessary capital to support preclinical research and development, acquiring equity stakes in exchange for their investment.

Ownership Structure

Founders typically retain a significant portion of ownership, often subject to vesting schedules. Early agreements often include provisions like vesting schedules to ensure founder commitment over time and buy-sell clauses to manage future liquidity events or potential founder departures.

Strategic Approach

The founding team's scientific vision and strategic approach to complement inhibition were fundamental in attracting initial investment and shaping the early distribution of control. This laid the groundwork for the company's future growth.

Understanding the initial ownership structure is vital when analyzing the evolution of the Apellis Pharmaceuticals company. Early Apellis investors played a crucial role in the company's development. The company's focus on complement inhibition and its early strategic decisions influenced its growth. For more insights into the competitive landscape of Apellis Pharmaceuticals, you can explore the Competitors Landscape of Apellis Pharmaceuticals.

Apellis Pharmaceuticals SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The evolution of Apellis Pharmaceuticals' ownership structure is marked by its initial public offering (IPO) on September 14, 2017. This event, which saw the company list on the Nasdaq Global Select Market under the ticker symbol APLS, was a pivotal moment. It shifted the ownership from primarily private equity and founder-held to a mix of public shareholders. This included institutional investors, mutual funds, and individual investors.

The IPO was crucial for Apellis Pharmaceuticals, transforming its financial landscape and opening doors to broader investment. This transition allowed the company to access significant capital, which supported research, development, and commercialization efforts. The shift also brought in a diverse group of stakeholders, each with unique perspectives and interests.

As of early 2025, institutional investors are the largest segment of Apellis Pharmaceuticals' ownership. Major stakeholders include asset management firms and mutual funds. For instance, Vanguard Group Inc. and BlackRock Inc. are typically among the largest institutional holders. As of March 31, 2025, The Vanguard Group, Inc. reported holding 11.52% of Apellis Pharmaceuticals, Inc. with 12,987,973 shares, while BlackRock Inc. held 8.94% with 10,076,029 shares. FMR LLC (Fidelity Management & Research Co.) also held a significant stake, with 9.87% and 11,128,754 shares.

Key Takeaways on Apellis Ownership

The ownership structure of Apellis Pharmaceuticals has evolved significantly since its IPO.

• Institutional investors now hold a major portion of the company's shares.
• The shift towards institutional ownership influences company strategy and governance.
• Understanding the ownership structure is crucial for assessing the company's direction.
• For more insights, explore the Marketing Strategy of Apellis Pharmaceuticals.

Apellis Pharmaceuticals PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors of Apellis Pharmaceuticals, as of early 2025, is composed of a diverse group of individuals with expertise in various fields relevant to the pharmaceutical industry, including clinical development, commercialization, and financial management. The board's composition reflects a balance between independent directors and executive directors, ensuring a robust oversight structure. The board's role is pivotal in guiding the company's strategic direction, overseeing its financial performance, and ensuring compliance with regulatory requirements. Understanding the Apellis company structure is key for Apellis investors.

The board's decisions are continuously scrutinized by institutional investors, who play a significant role in shaping the company's governance practices. The board's composition and independent oversight are critical for ensuring accountability to all shareholders and guiding the company through its clinical development and commercialization phases. The board typically includes a mix of independent directors, executive directors (such as the CEO), and sometimes representatives from significant early investors. The board's structure is designed to provide a balance of perspectives and expertise, ensuring that the company's interests are aligned with those of its shareholders. Understanding the Apellis ownership structure is crucial for anyone invested in Apellis stock.

The voting structure of Apellis Pharmaceuticals follows a one-share-one-vote principle, which is standard for most publicly traded companies in the United States. This means that each share of common stock grants one vote on matters brought before shareholders, such as the election of directors or approval of corporate actions. There is no public indication of dual-class shares or special voting rights that would grant outsized control to specific individuals or entities. This structure ensures that all shareholders have a proportional say in the company's governance. For more details, you can read about the Revenue Streams & Business Model of Apellis Pharmaceuticals.

Key Aspects of Apellis Pharmaceuticals' Board and Voting

The Board of Directors oversees Apellis Pharmaceuticals, ensuring strategic direction and compliance. The voting structure is based on a one-share-one-vote principle, promoting equitable shareholder influence.

• The board includes independent and executive directors.
• Institutional investors closely monitor the board's decisions.
• The company operates with a standard voting structure.
• The board's decisions are crucial for clinical development and commercialization.

Apellis Pharmaceuticals Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, the ownership structure of Apellis Pharmaceuticals has been influenced by key developments, particularly the commercialization of its approved therapies. The launch of EMPAVELI (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH) and SYFOVRE (pegcetacoplan injection) for geographic atrophy (GA) has attracted significant investor interest. This transition from a development-stage company to a revenue-generating entity often leads to increased institutional ownership, as seen across the biopharmaceutical sector.

Industry trends also play a role in shaping Apellis ownership. The rise of passive investment vehicles, like index funds and ETFs, has contributed to a broader institutional shareholder base. While this can diversify the investor pool, it might also reduce the influence of individual activist investors. As Apellis continues to raise capital for research and development, founder dilution is a natural part of the process.

Apellis Pharmaceuticals has not announced any privatization plans or major ownership changes related to succession. The company remains focused on expanding the indications for its approved products and advancing its pipeline. Future mergers, acquisitions, share buybacks, or secondary offerings could significantly alter the ownership structure. For more insights into the company's strategic direction, consider reading about the Growth Strategy of Apellis Pharmaceuticals.

Key Executives

The leadership team at Apellis includes key executives who influence the company's direction. The CEO and other top executives play crucial roles in strategic decisions and operational execution. Understanding the management structure provides insights into the decision-making processes.

Major Shareholders

Institutional investors often hold a significant portion of Apellis stock. Analyzing major shareholders offers insights into investor confidence and the potential for future strategic moves. Identifying these key stakeholders is important for understanding ownership dynamics.

Financial Performance

Apellis's financial results, including revenue and profitability, impact its Apellis investors and ownership structure. Strong financial performance can attract more investors and influence stock valuation. Monitoring financial metrics provides a clear picture of the company's health.

Future Outlook

The future of Apellis Pharmaceuticals depends on its pipeline, market trends, and strategic decisions. Understanding these factors is vital for assessing the company's long-term viability. The company's growth prospects will continue to shape its ownership dynamics.

Apellis Pharmaceuticals Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs